NCT07308756 Impact of Perioperative Dexmedetomidine and Esketamine on Postoperative Quality of Recovery
| NCT ID | NCT07308756 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Peking University First Hospital |
| Condition | General Anesthesia |
| Study Type | INTERVENTIONAL |
| Enrollment | 316 participants |
| Start Date | 2026-01-05 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 316 participants in total. It began in 2026-01-05 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
For patients after surgery, quality of recovery has significant impacts on the prognosis, quality of life, and rational allocation of medical resources. Dexmedetomidine and esketamine have each been used during the perioperative period and improved postoperative analgesia and subjective sleep quality. This 2x2 factorial trial is designed to explore the effects of dexmedetomidine, esketamine, and their combination on the quality of recovery in patients recovering from surgery under general anesthesia.
Eligibility Criteria
Inclusion Criteria: * Aged 18 years or over; * Scheduled to undergo surgery under general anesthesia, with an expected surgical duration of at least 1 hour; * Required patient-controlled intravenous analgesia after surgery. Exclusion Criteria: * Unable to communicate preoperatively due to visual, auditory, or verbal barriers or other reasons; * Severe bradycardia (heart rate \<50 bpm), sick sinus syndrome, or grade 2 or higher atrioventricular block without pacemaker; * History of hyperthyroidism or pheochromocytoma; * History of schizophrenia, epilepsy, Parkinson's disease, myasthenia gravis, or intracranial hypertension; * Intracranial tumor or neurosurgery; * Severe liver dysfunction (Child-Pugh class C), renal failure (requiring renal replacement therapy), or American Society of Anesthesiologists class IV or higher; * Enrolled in other clinical studies.
Contact & Investigator
Dong-Xin Wang, MD, PhD
PRINCIPAL INVESTIGATOR
Peking University First Hospital
Frequently Asked Questions
Who can join the NCT07308756 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying General Anesthesia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07308756 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07308756 currently recruiting?
Yes, NCT07308756 is actively recruiting participants. Contact the research team at wangdongxin@hotmail.com for enrollment information.
Where is the NCT07308756 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07308756 clinical trial?
NCT07308756 is sponsored by Peking University First Hospital. The principal investigator is Dong-Xin Wang, MD, PhD at Peking University First Hospital. The trial plans to enroll 316 participants.